Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The CONVINCE trial was a multinational, pragmatic, open-label, randomised controlled trial designed to evaluate benefits and harms of high-dose post-dilution haemodiafiltration (HDF) (convection volume ≥23 litres/1.73m2) compared with conventional high-flux haemodialysis (HD). The trial reported all-cause mortality benefit in patients undergoing HDF, however controversy exists regarding the entry criterion which may have selected a relatively healthier population, leading to results possibly not generalisable to the wider dialysis population. We sought to: 1. To assess the eligibility of patients in the ANZDATA Registry for inclusion within CONVINCE trial criteria; 2. To determine the association of high volume HDF or high flux haemodialysis with mortality in CONVINCE eligible patients.
Utilising data from the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), we sought to emulate the CONVINCE trial protocol and analysis in a retrospective observational study. As convection volume was recorded from 2019, all adult patients undergoing high-flux HD or high-dose HDF for at least 3 months at a frequency of at least 3 times per week from 2019 to 2023 were included. Exclusion criteria were death <3 months and living donor kidney transplantation within 6 months. Start time was defined as commencement of either HD or HDF and follow-up ended at death or transition to a different modality, including transplantation (whichever occurred earlier). Inverse-probability treatment weighing (IPTW) was used to adjust for baseline patient and dialysis characteristics and mortality was analysed using a Cox proportional hazards model.
Of 21,264 patients studied, 6557 (30.8%) would have been eligible for CONVINCE, of which 4836 received HD and 1721 received HDF. Eligible participants were more likely to receive treatments from metropolitan centres, be male, and have longer dialysis and commence dialysis with a native arteriovenous fistula compared to the rest of the ANZDATA population. There was no difference in age, mortality and comorbidities in eligible versus ineligible participants. Baseline characteristics for the CONVINCE eligible population are summarised (Table 1). Using IPTW to balance the characteristics below, there was no difference in all-cause mortality between those undertaking HD and HDF (HR 0.95, 95% CI: 0.83,1.09; p = 0.464).
Using a binational registry, 69% of patients would not be eligible for CONVINCE. This should be considered in applying the trial findings to a broader population. In this trial emulation, we were unable to demonstrate the mortality benefit seen in the CONVINCE randomised controlled trial.
